Australia markets close in 41 minutes

Trevi Therapeutics, Inc. (TRVI)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
3.1100-0.2300 (-6.89%)
At close: 04:00PM EDT
3.1100 0.00 (0.00%)
After hours: 04:22PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 225.76M
Enterprise value 157.46M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)3.41
Enterprise value/revenue N/A
Enterprise value/EBITDA -4.92

Trading information

Stock price history

Beta (5Y monthly) 0.97
52-week change 352.45%
S&P500 52-week change 333.89%
52-week high 34.0000
52-week low 30.9700
50-day moving average 33.0407
200-day moving average 32.5963

Share statistics

Avg vol (3-month) 3256.7k
Avg vol (10-day) 3580k
Shares outstanding 572.59M
Implied shares outstanding 672.59M
Float 843.5M
% held by insiders 11.25%
% held by institutions 177.21%
Shares short (13 Sept 2024) 41.39M
Short ratio (13 Sept 2024) 48.03
Short % of float (13 Sept 2024) 43.08%
Short % of shares outstanding (13 Sept 2024) 41.92%
Shares short (prior month 15 Aug 2024) 41.5M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)30 June 2024

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-30.88%
Return on equity (ttm)-48.09%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -43.03M
Net income avi to common (ttm)-38.77M
Diluted EPS (ttm)-0.3800
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)69.5M
Total cash per share (mrq)0.96
Total debt (mrq)1.19M
Total debt/equity (mrq)1.80%
Current ratio (mrq)10.68
Book value per share (mrq)0.91

Cash flow statement

Operating cash flow (ttm)-32.79M
Levered free cash flow (ttm)-19.17M